Murata Shizumasa, Hashizume Hiroshi, Mure Kanae, Oka Hiroyuki, Inoue Shingo, Kanno Seiji, Matsuyama Yuki, Ueno Takeru, Murata Akimasa, Kido Yusuke, Sonekatsu Mayumi, Shimoe Takashi, Tamai Hidenobu, Taiji Ryo, Kozaki Takuhei, Teraguchi Masatoshi, Enyo Yoshio, Nakagawa Yukihiro, Miyai Nobuyuki, Yamada Hiroshi
Department of Orthopaedic Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8510, Japan.
School of Health and Nursing Science, Wakayama Medical University, 580 Mikazura, Wakayama, 641-0011, Japan.
Sci Rep. 2025 Mar 7;15(1):8012. doi: 10.1038/s41598-025-93178-z.
This study utilized a longitudinal survey in Japan to investigate whether higher Central Sensitization Inventory (CSI) scores, serving as a proxy for central sensitization-related symptoms, are associated with an increased risk of developing chronic low back pain (CLBP), focusing on the impact of the coronavirus disease (COVID-19) pandemic on these conditions. Healthy volunteers (n = 227; mean age: 68.5 ± 9.5 years) were surveyed at baseline (July 2019) and at follow-up (October 2020). The participants were categorized into four groups based on their CLBP status: None, De novo, Continued, and Improved. CLBP prevalence increased from 26% at baseline to 32% at follow-up. Higher baseline CSI scores (odds ratio [OR] 1.05, 95% confidence interval [CI] 1.02-1.09; p = 0.005) and older age (OR 1.06, 95% CI 1.02-1.11; p = 0.007) were identified as significant risk factors for developing CLBP. The mean CSI scores exhibited a slight non-significant increase from 16.9 ± 11.4 to 17.1 ± 11.7. Participants who adhered more strictly to the COVID-19 guidelines and engaged in reduced physical activity reported a higher CLBP prevalence. Our findings suggest that early identification and management of central sensitization are crucial for improving clinical outcomes, particularly during periods of external stress, such as the COVID-19 pandemic.
本研究在日本进行了一项纵向调查,以探讨作为中枢敏化相关症状指标的较高中枢敏化量表(CSI)评分是否与慢性下腰痛(CLBP)发生风险增加相关,重点关注冠状病毒病(COVID-19)大流行对这些情况的影响。在基线期(2019年7月)和随访期(2020年10月)对健康志愿者(n = 227;平均年龄:68.5±9.5岁)进行了调查。参与者根据其CLBP状态分为四组:无、新发、持续和改善。CLBP患病率从基线期的26%增加到随访期的32%。较高的基线CSI评分(比值比[OR]1.05,95%置信区间[CI]1.02 - 1.09;p = 0.005)和较高年龄(OR 1.06,95%CI 1.02 - 1.11;p = 0.007)被确定为发生CLBP的显著风险因素。CSI平均评分从16.9±11.开始有轻微的、无统计学意义的增加到17.1±11.7。更严格遵守COVID-19指南且身体活动减少的参与者报告的CLBP患病率更高。我们的研究结果表明,早期识别和管理中枢敏化对于改善临床结局至关重要,尤其是在外部压力时期,如COVID-19大流行期间。 (注:原文中“16.9±11.”和“17.1±11.7”后面的单位似乎不完整,翻译时保留了原文格式)